Hair loss: The role of nutritional support in a comprehensive approach to hair loss treatment

Background. Telogen effluvium is the most common form of hair loss, which is manifested by the loss of more than 100 hairs in the telogen phase per day. There are various causes of hair loss, the main one being nutritional deficiencies, micro-, macronutrients and vitamins (zinc, iron, vitamin D, essential amino acids). Currently, there are no generally accepted clinical guidelines for the treatment of telogen effluvium, which makes it difficult to choose a therapeutic algorithm.

Aim. Conduct a comparative analysis of the outcomes associated with monotherapy and combination therapy that incorporates oral Pantovigar in patients experiencing telogen effluvium.

Materials and methods. The research included 29 female participants aged between 27 and 50 years, all diagnosed with telogen effluvium. The participants were randomly assigned to three distinct groups. The first group was treated with Pantovigar orally, in conjunction with a topical lotion designed to combat hair loss, which contained the active ingredient Microxidil. The second group received solely the topical lotion with Microxidil. The third group underwent treatment with Pantovigar orally and also utilized the topical lotion against hair loss containing the active complex Microxidil, and a course of mesotherapy with a placental preparation.

Results. The therapy exhibited significant clinical efficacy, evidenced by a decrease in hair loss, a reduction in the number of hairs in the telogen phase, and an increase in hair growth density per square centimeter as observed in the control phototrichogram. Additionally, the Pull-test yielded negative results. Patients reported enhanced volume and improved strength of their hair structure. The diagnostic procedure phototrichogram was performed twice during the study (at the start of therapy and after 3 months). Treatment was carried out for 3 months. In addition, patients were offered questionnaires on tolerability and assessment of the effectiveness of therapy.

Conclusion. The application of combination therapy involving the drug Pantovigar, along with a lotion containing the active complex Microxidil and mesotherapy using a placental product for skin rejuvenation, demonstrates a significant therapeutic effect when compared to the control group, which consisted of patients not receiving Pantovigar. The findings of this study offer compelling evidence supporting the use of targeted nutritional supplementation in the management of telogen effluvium.